Alexandra Leary

21PUBLICATIONS
244CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classifiedMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jan 15, 2026
ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial.

Guillaume Beinse, Valerie Taly, Alexandra Leary

|Jan 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Félix Blanc-Durand, Benoit You, Yahia Adnani

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Nov 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Claudia Marchetti, Gwenael Ferron, Olivier Colomban

|Jul 24, 2025
Clinical and biological characteristics associated with loss-of-heterozygosity in endometrial cancer.

Felix Blanc-Durand, Etienne Rouleau, Patricia Pautier

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

Pageof 4

Frequent Collaborators

7 joint publications

Félix Blanc-Durand

5 joint publications

Isabelle Ray-Coquard

4 joint publications

Coriolan Lebreton

4 joint publications

Benoit You